Literature DB >> 34265103

Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease.

Yoshito Nishimura1,2, David C Fajgenbaum3, Sheila K Pierson3, Noriko Iwaki4, Asami Nishikori5, Mitsuhiro Kawano6, Naoya Nakamura7, Koji Izutsu8, Kengo Takeuchi9,10,11, Midori Filiz Nishimura12, Yoshinobu Maeda13, Fumio Otsuka1, Kazuyuki Yoshizaki14, Eric Oksenhendler15,16, Frits van Rhee17, Yasuharu Sato5.   

Abstract

Thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly (TAFRO) syndrome is a heterogeneous entity manifesting with a constellation of symptoms described above that can occur in the context of idiopathic multicentric Castleman disease (iMCD) as well as infectious diseases, malignancies, and rheumatologic disorders. So, iMCD-TAFRO is an aggressive subtype of iMCD with TAFRO syndrome and often hyper-vascularized lymph nodes. Since we proposed diagnostic criteria of iMCD-TAFRO in 2016, we have accumulated new insights on the disorder and additional cases have been reported worldwide. In this systematic review and cohort analysis, we established and validated a definition for iMCD-TAFRO. First, we searched PubMed and Japan Medical Abstracts Society databases using the keyword "TAFRO" to extract cases. Patients with possible systemic autoimmune diseases and hematologic malignancies were excluded. Our search identified 54 cases from 50 articles. We classified cases into three categories: (1) iMCD-TAFRO (TAFRO syndrome with lymph node histopathology consistent with iMCD), (2) possible iMCD-TAFRO (TAFRO syndrome with no lymph node biopsy performed and no other co-morbidities), and (3) TAFRO without iMCD or other co-morbidities (TAFRO syndrome with lymph node histopathology not consistent with iMCD or other comorbidities). Based on the findings, we propose an international definition requiring four clinical criteria (thrombocytopenia, anasarca, fever/hyperinflammatory status, organomegaly), renal dysfunction or characteristic bone marrow findings, and lymph node features consistent with iMCD. The definition was validated with an external cohort (the ACCELERATE Natural History Registry). The present international definition will facilitate a more precise and comprehensive approach to the diagnosis of iMCD-TAFRO.
© 2021 Wiley Periodicals LLC.

Entities:  

Mesh:

Year:  2021        PMID: 34265103     DOI: 10.1002/ajh.26292

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   13.265


  12 in total

1.  Thrombocytopenia, anasarca, and severe inflammation.

Authors:  Amanallah Montazeripouragha; Christine M Campbell; James Russell; Nadia Medvedev; Daniel R Owen; Alison Harris; Fergal Donnellan; Iain McCormick; David C Fajgenbaum; Luke Y C Chen
Journal:  Am J Hematol       Date:  2022-07-19       Impact factor: 13.265

2.  How we manage idiopathic multicentric Castleman disease.

Authors:  Joshua D Brandstadter; David C Fajgenbaum
Journal:  Clin Adv Hematol Oncol       Date:  2022-09

Review 3.  Castleman disease.

Authors:  Antonino Carbone; Margaret Borok; Blossom Damania; Annunziata Gloghini; Mark N Polizzotto; Raj K Jayanthan; David C Fajgenbaum; Mark Bower
Journal:  Nat Rev Dis Primers       Date:  2021-11-25       Impact factor: 65.038

4.  Successful Treatment of Thrombocytopenia, Anasarca, Fever, Reticulin Myelofibrosis/Renal Insufficiency, and Organomegaly Syndrome Using Plasma Exchange Followed by Rituximab in the Intensive Care Unit.

Authors:  Yusuke Otsuka; Akihiro Shirakabe; Toshio Asayama; Hirotake Okazaki; Yusaku Shibata; Shota Shigihara; Tomofumi Sawatani; Norio Yokose; Kuniya Asai
Journal:  J Med Cases       Date:  2021-12-02

5.  Post-transplant Complication With TAFRO Features in a Patient With Acute Myeloid Leukemia.

Authors:  Kyosuke Yamaguchi; Yasushi Kubota; Hiroo Katsuya; Toshihiko Ando; Shinya Kimura
Journal:  Cureus       Date:  2022-03-31

6.  Increased mTORC2 pathway activation in lymph nodes of iMCD-TAFRO.

Authors:  Alexis D Phillips; Joseph J Kakkis; Patricia Y Tsao; Sheila K Pierson; David C Fajgenbaum
Journal:  J Cell Mol Med       Date:  2022-04-30       Impact factor: 5.295

7.  Idiopathic multicentric Castleman disease with positive antiphospholipid antibody: atypical and undiagnosed autoimmune disease?

Authors:  Yoshito Nishimura; Asami Nishikori; Haruki Sawada; Torrey Czech; Yuki Otsuka; Midori Filiz Nishimura; Hiroki Mizuno; Naoki Sawa; Shuji Momose; Kumiko Ohsawa; Fumio Otsuka; Yasuharu Sato
Journal:  J Clin Exp Hematop       Date:  2022-03-05

8.  Historical and pathological overview of Castleman disease.

Authors:  Midori Filiz Nishimura; Yoshito Nishimura; Asami Nishikori; Tadashi Yoshino; Yasuharu Sato
Journal:  J Clin Exp Hematop       Date:  2022-04-27

9.  Global public awareness of Castleman disease and TAFRO syndrome between 2015 and 2021: A Google Trends analysis.

Authors:  Yoshito Nishimura; Midori Filiz Nishimura; David C Fajgenbaum; Frits van Rhee; Yasuharu Sato; Fumio Otsuka
Journal:  EJHaem       Date:  2022-04-28

Review 10.  Castleman disease and TAFRO syndrome.

Authors:  Yasufumi Masaki; Kotaro Arita; Tomoyuki Sakai; Kazue Takai; Sadao Aoki; Hiroshi Kawabata
Journal:  Ann Hematol       Date:  2022-01-19       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.